HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools
00
Days
00
Hours
00
Mins
00
Sec
Register Now!
Market News Stocks News ETF News Crypto News

Soleno Therapeutics

Contributing Author

Recent Articles by Soleno Therapeutics

Dec-03
Soleno Therapeutics Announces the Passing of Board Member William G. Harris SLNO GlobeNewswire
Nov-24
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference SLNO GlobeNewswire
Nov-11
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement SLNO GlobeNewswire
Nov-04
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR SLNO GlobeNewswire
Oct-28
Soleno Therapeutics to Participate in Upcoming November Conferences SLNO GlobeNewswire
Oct-21
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET SLNO GlobeNewswire
Oct-13
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors SLNO GlobeNewswire
Aug-27
Soleno Therapeutics to Participate in Upcoming September Conferences SLNO GlobeNewswire
Aug-06
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results SLNO GlobeNewswire
Jul-28
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET SLNO GlobeNewswire
Jul-10
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock SLNO GlobeNewswire
Jul-10
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock SLNO GlobeNewswire
Jul-10
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 SLNO GlobeNewswire
Jul-01
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 SLNO GlobeNewswire
Jun-25
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference SLNO GlobeNewswire
Jun-20
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference SLNO GlobeNewswire
May-22
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome SLNO GlobeNewswire
May-21
Soleno Therapeutics to Participate in Upcoming June Conferences SLNO GlobeNewswire
May-20
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome SLNO GlobeNewswire
May-15
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 SLNO GlobeNewswire
May-13
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 SLNO GlobeNewswire
May-08
Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 SLNO GlobeNewswire
May-07
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results SLNO GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.